Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 上海仁度生物科技股份有限公司(公司简称:仁度生物,股票代码:688193)。仁度生物成立于2007年,是国内专注于RNA分子诊断技术与产品的高新技术企业,致力于开发、推广以实时荧光恒温扩增检测技术(简称SAT技术)为基础的RNA分子诊断产品。仁度生物拥有从诊断试剂到全自动配套仪器研发和生产的一整套自主知识产权核心技术。目前,公司已成功建立了SAT技术平台,有46项相关专利获得授权,20个产品获得NMPA注册证书并上市销售。与DNA分子诊断技术(PCR)相比,SAT技术具有灵敏度高、特异性强、交叉污染低和易于实现全自动高通量检测等特点。基于SAT技术的分子诊断产品可广泛应用于临床检测、血液筛查、食品安全检测、传染性疾病的应急防控和快速反应等多个领域。 | ||||||||||||||||||||||||
Main Business | 开发临床需求尚未满足、临床价值高、市场应用广泛的创新诊断技术和产品,深度打造“核心原料酶+试剂+仪器+第三方检测服务”一体化经营模式,为生殖、呼吸、消化、血液、肿瘤、食品、环境安全等领域病原体的精准诊断、有效防控和个性化诊疗提供解决方案。 | ||||||||||||||||||||||||
Legal Representative | 居金良 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 蔡廷江 | ||||||||||||||||||||||||
Solicitors | 北京市嘉源律师事务所 | ||||||||||||||||||||||||
Auditors | 立信会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 021-50720069 | ||||||||||||||||||||||||
Fax No | 021-50720069 | ||||||||||||||||||||||||
Website | www.rdbio.com | ||||||||||||||||||||||||
ir@rdbio.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 30/03/2022 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.210 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 24.069 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 1.227B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |